1. PTH-137 Safety and efficacy of simeprevir (SMV) plus PEG-IFN/RBV in treatment-naÏve chronic hepatitis c genotype 1 patients eligible for 12 weeks of treatment. (22nd June 2015) Authors: Foster, GR; Asselah, T; Moreno, C; Sarrazin, C; Gschwantler, M; Craxi, A; Buggisch, P; Ryan, R; Lenz, O; Van Dooren, G; Lonjon-Domanec, I; Schlag, M; Buti, M Journal: Gut Issue: Volume 64(2015)Supplement 1 Page Start: A468 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗